A clinical study of Xilei Powder, metronidazole, gentamicin combined with dexamethasone retention enema to treat low anterior rectal resection syndrome

doi:10.3877/cma.j.issn.2095-3224.2021.03.005

Abstract

Abstract:

Objective

To study the clinical efficacy of Xilei powder, metronidazole, gentamicin combined with dexamethasone retention enema for low anterior rectal resection syndrome.

Methods

A total of 88 patients who had low anterior resection syndrome after undergoing low anus-preserving radical rectal cancer surgery in the fourth hospital of Hebei medical university from January 2017 to May 2018 were included as study subjects. According to the random number table method, they were divided into the observation group (n=44) and the control group (n=44). The control group was treated with conventional postoperative education, diet adjustment, and anal expansion. The observation group was given Xilei Powder, metronidazole, gentamicin combined with dexamethasone retention enema on this basis. The low anterior resection syndrome (LARS) score, serotonin level (5-HT) were compared between the two groups of patients.

Results

The score of the low anterior resection syndrome (LARS) scale in the observation group was significantly lower than that in the control group, and the difference was statistically significant (t=7.218, P＜0.05); the expression of 5-HT in the observation group was significantly higher than that in the control group, and the difference was statistically significant (χ²=9.639, P＜0.05).

Conclusion

Xilei powder, metronidazole, gentamicin combined with dexamethasone retention enema has good clinical efficacy in treating rectal resection syndrome, and its mechanism of action may be related to drugs that stimulate the release of 5-HT substances in the rectal mucosa and regulate defecation.

Key words: Rectum, Xilei powder, Retention enema, The low anterior resection syndrome, LARS rating scale

Youqiang Liu, Xuhua Hu, Yang Mi, Zhenzhen Wang, Bin Yu, Guiying Wang. A clinical study of Xilei Powder, metronidazole, gentamicin combined with dexamethasone retention enema to treat low anterior rectal resection syndrome[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(03): 250-254.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2021.03.005

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2021/V10/I03/250

Figures/Tables 4

References 17

1	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
2	Tilney HS, Heriot AG, Purkayastha S, et al. A national perspective on the decline of abdominoperineal resection for rectal cancer[J]. Ann Surg, 2008, 247(1): 77 -84.
3	吴超, 汪全新, 卢晓明, 等. 腹腔镜改良经肛门结肠肛管吻合术切除低位直肠癌保肛手术的临床疗效分析[J]. 临床外科杂志, 2016, 24(6): 437-439.
4	李泽平, 袁成浩, 陈云. 低位直肠癌应用腹部无切口腹腔镜直肠癌根治术的临床体会[J]. 结直肠肛门外科, 2016, 22(2): 195-198.
5	高加勒, 安勇博, 汪栋, 等. 直肠癌保肛术后短期生活质量研究现状[J].中华胃肠外科杂志, 2020, 23(4): 415-420.
6	Bregendahl S, Emmertsen KJ, Lous J, et al. Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study[J]. Colorectal Dis, 2013, 15(9): 1130-1139.
7	Bryant CL, Lunniss PJ, Knowles CH, et al. Anterior resection syndrome[J]. Lancet Oncol, 2012, 13(9): e403-e408.
8	Emmertsen KJ, Laurberg S. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer[J]. Br J Surg, 2013, 100(10): 1377-1387.
9	Chen TY, Wiltink LM, Nout RA, et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial[J]. Clin Colorectal Cancer, 2015, 14(2): 106-114.
10	戴志慧, 杜金林, 王建平, 等. 改良横结肠保护性造口及皮下腹腔外造口关闭在腹腔镜中低位直肠癌前切除术的应用[J].中华胃肠外科杂志, 2020, 23(7): 714-716.
11	闫晶晶, 牟绍玉, 谭人福, 等. 直肠癌直肠前切除综合征评分表中文版的实证研究[J]. 解放军护理, 2015, 32(4): 12-15.
12	李兴旺, 胡军红. 直肠癌术后前切除综合征的研究进展[J/CD].中华结直肠疾病电子杂志, 2019, 8(2): 170-175.
13	师博, 唐劲, 田利军, 等. 直肠癌患者发生低位前切除综合征的相关危险因素[J]. 中国现代医学杂志, 2019, 29(12): 93-96.
14	吴晓丹, 符春凤, 陈依琳, 等. 生物反馈联合盆底肌锻炼对直肠癌低位保肛患者低位前切除综合征的作用[J]. 中华医学杂志, 2019, 99(30): 2337-2343.
15	周继勇, 陈振华, 曹泮悬, 等. 锡类散加味灌肠治疗溃疡性结肠炎29例[J]. 中医杂志, 2011, 22(21): 1862-1864.
16	俞媛洁, 陈继红. 5-羟色胺与胃肠动力障碍的关系[J]. 医学综述, 2016, 22(4): 18-21.
17	周昱. 直肠粘膜5-羟色胺表达水平与直肠癌前切除患者生活质量及前切除综合征发病的关系[J]. 河北医学, 2016, 22(10): 1676-1679.

观察指标	观察组（n = 44）	对照组（n = 44）	t/χ²值	P值
性别			0.210	0.674
女	15	13
男	29	31
中位年龄（岁）	53.56±6.9	54.21±7.1	0.436	0.664
中位肿瘤位置（cm）	6.84±0.43	6.71±0.50	1.308	0.195
肿瘤分期^a			0.050	0.823
Ⅱ期	15	16
Ⅲ期	29	28
肿瘤分化程度			0.826	0.662
低分化	8	7
中分化	31	29
高分化	5	8
手术方式			0.104	0.747
腹腔镜手术	38	39
开腹手术	6	5
术后辅助治疗			0.279	0.597
是	36	34
否	8	10
辅助治疗方案			0.515	0.773
CapeOX^b	23	20
mFOLFOX6^c	6	8
单药口服	7	6
BMI^d指数	24.37±2.34	25.01±1.95	1.394	0.167
保护性造口			0.306	0.580
是	9	7
否	35	37

观察指标	观察组（n = 44）	对照组（n = 44）	t/χ²值	P值
性别			0.210	0.674
女	15	13
男	29	31
中位年龄（岁）	53.56±6.9	54.21±7.1	0.436	0.664
中位肿瘤位置（cm）	6.84±0.43	6.71±0.50	1.308	0.195
肿瘤分期^a			0.050	0.823
Ⅱ期	15	16
Ⅲ期	29	28
肿瘤分化程度			0.826	0.662
低分化	8	7
中分化	31	29
高分化	5	8
手术方式			0.104	0.747
腹腔镜手术	38	39
开腹手术	6	5
术后辅助治疗			0.279	0.597
是	36	34
否	8	10
辅助治疗方案			0.515	0.773
CapeOX^b	23	20
mFOLFOX6^c	6	8
单药口服	7	6
BMI^d指数	24.37±2.34	25.01±1.95	1.394	0.167
保护性造口			0.306	0.580
是	9	7
否	35	37

组别	例数	治疗前	治疗后
观察组	44	30.47±5.31	15.34±4.07^a
对照组	44	29.98±5.27	23.52±6.32^b
ｔ值		0.435	7.218
P值		0.665	＜0.0001

组别	例数	治疗前	治疗后
观察组	44	30.47±5.31	15.34±4.07^a
对照组	44	29.98±5.27	23.52±6.32^b
ｔ值		0.435	7.218
P值		0.665	＜0.0001

组别	5-HT的免疫组化染色结果判读
组别	-	+	++	+++
观察组	11（25%）	10（22.7%）	14（31.8%）	9（20.5%）
对照组	10（22.7%）	9（20.5%）	15（34.1%）	10（22.7%）
χ²值	0.187
P值	0.980

Please choose a citation manager

Content to export